A Phase 1, Open-Label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of Single Oral Dose [14C]-BIIB091 in Healthy Male Participants
Latest Information Update: 27 May 2024
At a glance
- Drugs BIIB 091 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen
- 22 May 2024 Status changed from active, no longer recruiting to completed.
- 13 May 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2024 Status changed from not yet recruiting to recruiting.